News | May 11, 2009

PET/CT Bone Imaging Trial Enrolls First 10 Patients

May 11, 2009 - The Academy of Molecular Imaging (AMI) is pleased to announce that its randomized, multicenter trial investigating the use of 18F-sodium fluoride PET/CT (18F-NaF) to detect bony metastases has enrolled its first 10 patients. This study compares conventional planar 99mTc-MDP bone imaging with 18F-NaF PET/CT in patients with breast, prostate and non-small cell lung cancers.

The protocol was developed in conjunction with the FDA and CMS, and calls for data on more than five hundred patients. The University of California-Los Angeles Medical Center, the VA Greater Los Angeles Healthcare Systems and Scottsdale Medical Imaging have all begun imaging patients.

“This exciting development is the culmination of many months’ work and an extraordinary level of collaboration,” reported Johannes Czernin, M.D., the principal investigator for the study. “While AMI is the IND holder, this important research is a result of cooperative efforts between 13 clinical sites, AMI and the molecular imaging industry. Siemens/PETNET Solutions furnished these initial 18F-NaF doses and GE Healthcare and IBA Molecular will also provide doses in the future.”

Cancer patients undergo more than 2 million planar 99mTc-MDP scans each year to determine whether the cancer has spread to their bones. 18F-NaF PET/CT bone scanning may have advantages over this conventional method because it is able to find smaller metastases and differentiate more accurately between cancerous and non-cancerous conditions.

“Cancer patients may receive better and more timely treatment if we are able to improve our ability to detect the spread of their disease earlier and more accurately,” said Ed Coleman, M.D., of Duke University Medical Center, which along with St. Louis University Hospital expects to begin enrolling participants soon. “This clinical trial is an example of the PET imaging community’s commitment to improve treatment and patient outcomes using scientifically rigorous research methods and analyses.”

Eight other sites are expected to participate upon IRB approval: Dartmouth-Hitchcock Medical Center, Stanford University Medical Center, Cedars-Sinai Medical Center, Washington University Medical Center, University of Utah Health Sciences Center, Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center and the University of Zurich.

For more information: www.ami-imaging.org

Related Content

SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
FDG-PET/CT Predicts Melanoma Patients' Response to Immune Checkpoint Inhibitor Therapy
News | PET-CT | September 07, 2017
September 7, 2017 — Advanced melanoma has a poor prognosis, but immune checkpoint inhibitor therapy can be effective
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Overlay Init